Acute Gouty Arthritis

Metabolic Diseases
4
Pipeline Programs
3
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
2
ACZ885Phase 35 trials
Canakinumab pre-filled syringePhase 31 trial
Active Trials
NCT01593527Withdrawn0Est. Sep 2012
NCT01576367Completed17Est. Oct 2015
NCT01470989Completed136Est. May 2013
+3 more trials
Atom Therapeutics
Atom TherapeuticsChina - Suzhou
1 program
1
ABP-745 Dose APhase 21 trial
Active Trials
NCT07145229RecruitingEst. Jun 2026
Swedish Orphan Biovitrum
1 program
1
Anakinra 100 mgPhase 21 trial
Active Trials
NCT03002974CompletedEst. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisACZ885
NovartisACZ885
NovartisACZ885
NovartisCanakinumab pre-filled syringe
NovartisACZ885
Atom TherapeuticsABP-745 Dose A
Swedish Orphan BiovitrumAnakinra 100 mg
NovartisACZ885
NovartisACZ885
NovartisACZ885
NovartisACZ885
NovartisACZ885

Clinical Trials (12)

Total enrollment: 692 patients across 12 trials

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Start: Sep 2012Est. completion: Sep 20120
Phase 3Withdrawn

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Start: Jan 2012Est. completion: Oct 201517 patients
Phase 3Completed

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Start: Nov 2011Est. completion: May 2013136 patients
Phase 3Completed
NCT01356602NovartisCanakinumab pre-filled syringe

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start: May 2011Est. completion: Sep 2012397 patients
Phase 3Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Start: Nov 2010Est. completion: Nov 201417 patients
Phase 3Completed

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Start: Aug 2025Est. completion: Jun 2026
Phase 2Recruiting

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

Start: Dec 2016Est. completion: Aug 2019
Phase 2Completed

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

Start: Oct 2010Est. completion: Jun 201420 patients
Phase 2Completed

Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Start: Aug 200711 patients
Phase 1/2Terminated

Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Start: Dec 200626 patients
Phase 1/2Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

Start: Dec 2006Est. completion: Dec 200748 patients
Phase 1Completed

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Start: Jul 200620 patients
Phase 1Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 692 patients
3 companies competing in this space